Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (Diluted Average) (2019 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $111.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 17.21% to $111.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $111.1 million through Dec 2025, up 17.21% year-over-year, with the annual reading at $111.1 million for FY2025, 17.21% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $111.1 million in Q4 2025 for Rocket Pharmaceuticals, roughly flat from $110.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $111.1 million in Q4 2025 to a low of $61.6 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $83.0 million across 5 years, with a median of $81.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 3.83% in 2022 and later rose 26.34% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $63.2 million in 2021, then increased by 7.77% to $68.1 million in 2022, then increased by 23.27% to $84.0 million in 2023, then grew by 12.85% to $94.8 million in 2024, then increased by 17.21% to $111.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for RCKT at $111.1 million in Q4 2025, $110.9 million in Q3 2025, and $110.6 million in Q2 2025.